NextCure, Inc. (NXTC)

NextCure's stock has been impacted by several events in the past six months. The company reported that its Q2 loss widened by 71% on August 7, 2025. Promising preclinical data for NC605 led to a stock price surge around July 24-25, 2025. A partnership with Simcere Zaiming for SIM0505 was announced on June 16, 2025. A business update and Q3 2025 financial results were provided on November 5, 2025. Ladenburg Thalmann upgraded NextCure's rating on November 7, 2025. A private placement of common stock, raising $21.5 million, was announced on November 12, 2025, causing a 15% share jump and was completed on November 17, 2025. NextCure filed for a 2.52 million share offering by selling stockholders on November 27, 2025. On January 23, 2026, a business update included clinical progress for SIM0505 and LNCB74, a preliminary year-end 2025 cash position of approximately $41.8 million, and a delay in LNCB74 trial data to the second half of 2026. Timothy Mayer received employee stock options on January 30, 2026.

As a clinical-stage biopharmaceutical company, NextCure, Inc. does not currently have commercialized products or services that would exhibit direct demand seasonality. The demand for their future products, once approved and commercialized, would likely be driven by medical need and treatment efficacy rather than seasonal patterns.

NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing immunomedicines for cancer and other immune-related diseases. The company operates in the Healthcare sector, specifically the Biotechnology & Medical Research industry, and uses its FIND-IO discovery technology to identify novel targets based on immunomodulatory function. Its major product candidates include LNCB74, NC410, NC525, NC181, NC605, and SIM0505.

NextCure, Inc. is headquartered in Beltsville, Maryland, USA. While its primary operations are based in the United States, the company has an international scope in its product development and potential market reach. For instance, NextCure acquired global rights to its SIM0505 program, excluding Greater China where its partner Simcere Zaiming retains rights, and has initiated U.S. trial enrollment for this candidate following dose escalation studies in China.

NextCure's brand reputation over the past year is generally positive among analysts, with a consensus rating of "Strong Buy" or "Moderate Buy." The company's stock performance has exceeded the broader U.S. market and matched the U.S. Biotechs industry over the last year. Positive events contributing to its reputation include encouraging preclinical data for its drug candidates and strategic partnerships. However, some express concerns regarding a significant reduction in the company's projected enterprise value and the inherent risks associated with clinical development.

NextCure, Inc. has 19 institutional owners and shareholders, holding a total of 859,907 shares. Major institutional owners include Sofinnova Investments, Inc., Affinity Asset Advisors, LLC, Pfizer Inc, Vanguard Group Inc, Cable Car Capital LLC, Acadian Asset Management Llc, BlackRock, Inc., Renaissance Technologies Llc, Geode Capital Management, Llc, and Sio Capital Management, LLC. Insiders collectively own 14.79% of the company's shares.